<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>16527169</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Monreal Bosch, M</dc:author>
<dc:description xml:lang="en">The last guidelines on treatment of venous thromboembolic disease recommend the use of unfractionated heparin (UFH) or low molecular weight heparin (LMWH). In the case of deep venous thrombosis in out-patients, LMWH is preferred, associated to dicumarinics from the first day. In regards to prophylaxis, administration of UFH or LMWH is recommended in surgical patients of moderate to high risk but not in those undergoing minor surgery, under 40 years and without other risk factors. In patients with acute coronary syndrome without ST elevation, the administration of LMWH at fixed doses together with platelet antiaggregants is recommended. In patients with acute cerebral ischemia and without other criteria for thrombolytic treatment, treatment with heparin is not recommended but rather the administration of platelet antiaggregants.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2006 Feb </dc:date>
<dc:title xml:lang="es">Indicaciones actuales del tratamiento con heparinas.</dc:title>
<dc:title xml:lang="en">[Current indications of heparin treatment].</dc:title>
<dc:publisher>Revista clinica espanola</dc:publisher>
</metadata>
</record>
</pubmed-document>
